Illumina (NASDAQ:ILMN) Director Sells 106,543 Shares

Illumina, Inc. (NASDAQ:ILMN) Director Keith Meister sold 106,543 shares of Illumina stock in a transaction on Wednesday, August 26th. The stock was sold at an average price of $225.46, for a total value of $24,021,184.78. Following the completion of the transaction, the director owned 1,172,289 shares in the company, valued at $264,304,277.94. The trade was a 8.33% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link.

Illumina Trading Up 1.3%

Shares of NASDAQ ILMN traded up $2.85 during mid-day trading on Thursday, hitting $227.69. 1,937,136 shares of the company traded hands, compared to its average volume of 2,109,322. Illumina, Inc. has a 1 year low of $88.00 and a 1 year high of $231.81. The stock has a market capitalization of $34.38 billion, a price-to-earnings ratio of 42.48, a PEG ratio of 3.16 and a beta of 1.45. The company has a quick ratio of 1.40, a current ratio of 1.80 and a debt-to-equity ratio of 0.53. The business has a 50 day moving average of $192.98 and a two-hundred day moving average of $155.18.

Illumina (NASDAQ:ILMN) last issued its quarterly earnings results on Thursday, July 30th. The life sciences company reported $1.31 earnings per share for the quarter, topping analysts’ consensus estimates of $1.23 by $0.08. The firm had revenue of $1.16 billion for the quarter, compared to analysts’ expectations of $1.13 billion. Illumina had a return on equity of 29.84% and a net margin of 18.36%.Illumina’s revenue was up 9.4% on a year-over-year basis. During the same quarter last year, the business posted $1.19 EPS. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, sell-side analysts anticipate that Illumina, Inc. will post 5.36 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

ILMN has been the topic of a number of recent analyst reports. Piper Sandler restated an “overweight” rating and set a $225.00 price target (up from $200.00) on shares of Illumina in a report on Monday, August 3rd. Canaccord Genuity Group lifted their price objective on shares of Illumina from $190.00 to $205.00 and gave the stock a “hold” rating in a research report on Monday, August 3rd. Royal Bank Of Canada boosted their target price on shares of Illumina from $170.00 to $230.00 and gave the company an “outperform” rating in a research note on Friday, July 31st. TD Cowen raised their target price on Illumina from $192.00 to $210.00 and gave the stock a “hold” rating in a research report on Friday, July 31st. Finally, Sanford C. Bernstein reissued a “market perform” rating and issued a $215.00 price objective on shares of Illumina in a research note on Friday, July 31st. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, six have given a Hold rating and two have given a Sell rating to the stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus target price of $188.40.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. California State Teachers Retirement System increased its position in Illumina by 16,869.5% in the 2nd quarter. California State Teachers Retirement System now owns 40,144,099 shares of the life sciences company’s stock worth $7,058,537,000 after purchasing an additional 39,907,533 shares during the last quarter. Capital World Investors grew its stake in shares of Illumina by 0.6% in the 4th quarter. Capital World Investors now owns 20,101,173 shares of the life sciences company’s stock valued at $2,636,483,000 after buying an additional 124,323 shares in the last quarter. BlackRock Inc. acquired a new position in Illumina in the second quarter worth approximately $3,374,423,000. State Street Corp increased its holdings in Illumina by 3.2% in the fourth quarter. State Street Corp now owns 6,190,114 shares of the life sciences company’s stock worth $811,895,000 after buying an additional 190,324 shares during the last quarter. Finally, WCM Investment Management LLC raised its position in Illumina by 45.5% during the first quarter. WCM Investment Management LLC now owns 5,923,173 shares of the life sciences company’s stock valued at $715,579,000 after acquiring an additional 1,851,848 shares in the last quarter. Hedge funds and other institutional investors own 89.42% of the company’s stock.

About Illumina

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.